Sorafenib (Nexavar, BAY 43-9006) : Bayer/Onyx : Oral cystostatic Raf kinase inhibitor

Phase II Study of BAY 4309006 (sorafenib) in Patients with Relapsed NSCLC (ASCO)
ASCO 2006 abstract of a phase II study that concluded that sorafenib appears to be well-tolerated and active against relapsed NSCLC. [5/06]

Nexavar (sorafenib) (Bayer/Onyx Pharmaceuticals)
Describes BAY 43-9006 (sorafenib) and how may work in treating cancer. Includes a review of current and previous clinical trials.

Sorafenib (Nexavar, BAY 43-9006) - Recent MEDLINE Abstracts (PubMed)

Sorafenib (Nexavar, BAY 43-9006)- Clinical Trials (ClinicalTrials.com)